Literature DB >> 29393251

The Impact of Skeletal Muscle Depletion on Head and Neck Squamous Cell Carcinoma.

Daisuke Nishikawa, Nobuhiro Hanai, Hidenori Suzuki, Yusuke Koide, Shintaro Beppu, Yasuhisa Hasegawa.   

Abstract

BACKGROUND: Skeletal muscle depletion and sarcopenia have been reported as poor prognostic factors for several types of cancer. The aim of this study was to investigate the prognostic impact of skeletal muscle depletion and sarcopenia on the outcomes in head and neck cancer patients.
METHODS: Patients with head and neck squamous cell carcinoma (HNSCC) treated from January 2013 to June 2014 were included in this study. The pretreatment cross-sectional area of skeletal muscle at the third lumbar vertebra (L3) was measured by computed tomography image analysis using the ImageJ software. L3 skeletal muscle index (SMI) and fat-free mass (FFM) were calculated.
RESULTS: Eighty-five patients with HNSCC were included. The cut-off value of sarcopenia was set at SMI <46.7 cm2/m2 (males) and 30.3 cm2/m2 (females). The cut-off value of FFM was set at 42.3 kg (males) and 30.6 kg (females). Patients with a low SMI (sarcopenia) and low FFM had a significantly poorer prognosis than others, especially those who received definitive radiotherapy. Sarcopenia and low FFM are independent factors for poor prognosis in patients with HNSCC.
CONCLUSION: The skeletal muscle area at L3 should be calculated when considering treatment options for head and neck cancer.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Fat-free mass; Head and neck cancer; ImageJ; Sarcopenia; Skeletal muscle index

Mesh:

Substances:

Year:  2018        PMID: 29393251     DOI: 10.1159/000485515

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  15 in total

1.  Adverse Outcomes after Advanced EVAR in Patients with Sarcopaenia.

Authors:  Abdullah O Alenezi; Elizabeth Tai; Arash Jaberi; Andrew Brown; Sebastian Mafeld; Graham Roche-Nagle
Journal:  Cardiovasc Intervent Radiol       Date:  2021-01-03       Impact factor: 2.740

Review 2.  Impact and Treatment of Sarcopenia in Patients Undergoing Radiotherapy: A Multidisciplinary, AMSTAR-2 Compliant Review of Systematic Reviews and Metanalyses.

Authors:  Federica Medici; Alberto Bazzocchi; Milly Buwenge; Alice Zamagni; Gabriella Macchia; Francesco Deodato; Savino Cilla; Pierandrea De Iaco; Anna Myriam Perrone; Lidia Strigari; Stefania Rizzo; Alessio G Morganti
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy.

Authors:  Ryusuke Shodo; Keisuke Yamazaki; Yushi Ueki; Takeshi Takahashi; Arata Horii
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-08       Impact factor: 2.503

4.  Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer.

Authors:  N Chargi; S I Bril; M H Emmelot-Vonk; R de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-04       Impact factor: 2.503

5.  CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer.

Authors:  Aniek T Zwart; Anouk van der Hoorn; Peter M A van Ooijen; Roel J H M Steenbakkers; Geertruida H de Bock; Gyorgy B Halmos
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-05-27       Impact factor: 12.910

6.  Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma.

Authors:  Anna C H Willemsen; Ann Hoeben; Roy I Lalisang; Ardy Van Helvoort; Frederik W R Wesseling; Frank Hoebers; Laura W J Baijens; Annemie M W J Schols
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-09-19       Impact factor: 12.910

Review 7.  Nutritional Deficiencies in Radiotherapy-Treated Head and Neck Cancer Patients.

Authors:  Tomasz Powrózek; Joanna Dziwota; Teresa Małecka-Massalska
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

8.  Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis.

Authors:  Alexey Surov; Andreas Wienke
Journal:  Ther Adv Med Oncol       Date:  2021-05-13       Impact factor: 8.168

9.  Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer.

Authors:  Joon-Kee Yoon; Jeon Yeob Jang; Young-Sil An; Su Jin Lee
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

10.  Body Composition Evaluation in Head and Neck Cancer Patients: A Review.

Authors:  Inês Almada-Correia; Pedro Miguel Neves; Antti Mäkitie; Paula Ravasco
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.